Form 8-K

8-K — Lantern Pharma Inc.

Accession: 0001493152-26-023758

Filed: 2026-05-15

Period: 2026-05-15

CIK: 0001763950

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001763950

2026-05-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 15, 2026

Lantern

Pharma Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1920

McKinney Avenue, 7th Floor

Dallas,

Texas

75201

(Address

of Principal Executive Offices)

(Zip

Code)

(972)

277-1136

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act: Common Stock

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value

LTRN

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first

quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

The

information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless

of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Exhibit

Description

99.1

Press Release dated May 15, 2026 announcing financial results for first quarter ended March 31, 2026.

104

Cover

Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Lantern

Pharma Inc.,

Delaware Corporation

Dated:

May 15, 2026

By:

/s/

David R. Margrave

David

R. Margrave, Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

NEWS

RELEASE

Lantern

Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Disciplined

Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai

Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million

● Q1

net loss reduced 27% year-over-year while progressing multiple precision oncology programs

● Commercial

introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built

for rare and complex cancer drug development

● Successful

outcome from Type C meeting request with the FDA focused on the LP-300 HARMONIC™ Clinical

Trial

● Pediatric

brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therapeutics

● Strategic

plan to create an independent entity composed of withZeta.ai assets

● Financial

Position: Cash, cash equivalents, and marketable securities were approximately $6.3 million

as of March 31, 2026; together with an additional approximately $4.4 million in gross proceeds

from the May 14, 2026 financing, the Company’s pro forma liquidity is expected to fund

operations into the middle of the first quarter of 2027.

DALLAS—(BUSINESS

WIRE)— Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary

RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology

drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2026,

and provided an update on its portfolio of AI-driven drug candidates and AI platforms.

The

first quarter of 2026 was defined by capital-efficient execution across Lantern’s clinical and AI platform pipelines. The Company

advanced multiple clinical-stage programs through meaningful regulatory and scientific milestones, including a successful outcome from

an FDA Type C meeting interaction on the Phase 2 HARMONIC™ trial of LP-300 and IND clearance for the first pediatric CNS cancer

program of wholly-owned subsidiary Starlight Therapeutics, while reducing research and development spend by 47% year-over-year. In parallel,

Lantern moved its proprietary AI infrastructure from internal capability to external commercial product with the launch of withZeta.ai,

the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development. The recent fundraise of

up to $9.25 million (which includes the potential future exercise of warrants) further strengthens the Company’s balance sheet

and supports continued advancement of both its clinical pipeline and its AI commercialization strategy.

“The

first quarter of 2026 demonstrated the operating discipline and capital-efficient execution that we believe is differentiating Lantern

from other clinical-stage and AI-driven oncology companies,” said Panna Sharma, President and CEO of Lantern Pharma. “We

reduced our R&D spend by 47% year-over-year while simultaneously advancing multiple clinical programs through important regulatory

milestones, achieving a successful outcome from our Type C meeting request with the FDA on the HARMONIC™ trial, and clearing the

path for Starlight Therapeutics’ first pediatric brain cancer trial. This level of milestone delivery on a tightly disciplined

budget reflects exactly what our AI-driven drug development model was designed to do — develop more programs, more quickly, and

at a fraction of the historical cost of biopharma R&D.”

addition to Lantern’s clinical pipeline advancements, the first quarter also marked a pivotal evolution in the commercialization

of the Company’s AI assets. With the public launch of withZeta.ai and the continued global expansion of the RADR®

platform through the Company’s initiation of an AI Center of Excellence in India, Lantern is now operating two distinct value-creation

engines: a clinical-stage drug development business aimed at advancing therapies across solid tumors, blood cancers, and pediatric brain

cancers; and an AI platform business addressing the multi-billion-dollar opportunity in AI-enabled drug discovery and rare cancer research.

To accelerate value realization across both engines, the Company has announced a strategic plan to create an independent business entity

composed of its withZeta.ai platform assets, intended to access dedicated funding sources and pursue valuation distinct from clinical

drug development operations.

“withZeta.ai

represents Lantern’s first agentic-based commercial AI product, and we believe it is positioned to capture a meaningful share of

what we view as a $20 to $50 billion near-term market opportunity in AI-driven drug development,” continued Mr. Sharma.

“Separating our withZeta.ai assets into an independent entity is intended to unlock dedicated funding, attract specialized talent,

and allow investors to value each business — clinical drug development and AI platforms — on its own terms. Combined with

the recent financing, which extends our operating runway into the first quarter of 2027, Lantern enters the remainder of 2026 with a

stronger balance sheet, a sharper commercial focus, and a portfolio of AI-driven oncology drug candidates with an estimated combined

annual market potential exceeding $15 billion.”

Clinical

Pipeline Developments

Lantern’s

AI-driven clinical pipeline encompasses multiple drug candidates across solid tumors, blood cancers, and pediatric oncology, with a combined

estimated annual market potential exceeding $15 billion. The portfolio includes a Phase 2 clinical program (LP-300) in NSCLC focused

on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase 1b/2 trials (LP-184) in precision, biomarker-defined

solid tumors; and an ongoing Phase 1 program in hematologic malignancies and adult soft tissue sarcomas (LP-284). Additionally, through

wholly-owned subsidiary Starlight Therapeutics, the Company has a planned Phase 1 pediatric CNS cancer trial and a planned Phase 1b trial

in adult relapsed glioblastoma (GBM) in combination with spironolactone, both with STAR-001 (LP-184). Each program has been guided by

the RADR® platform’s AI-driven insights. On average, Lantern’s newly developed drug programs have been advanced

from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program.

LP-300

HARMONIC™ Trial: Successful Type C Meeting Request Outcome and Path Forward

May 2026, Lantern received responses from its Type C meeting request to the U.S. Food and Drug Administration to discuss proposed protocol

amendments to the Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma.

The Company received a successful outcome from the meeting request and no objections from the FDA on key proposed amendments to the study,

providing an emergent regulatory path forward for the trial.

● Focused

Patient Enrollment: Future HARMONIC™ enrollment will focus on patients with the

EGFR exon 21 L858R mutation, a subtype of tyrosine kinase mutations that demonstrates

lower sensitivity and inferior treatment outcome to osimertinib based therapy. Preliminary

analysis of study data suggests that patients with this mutation may derive greater clinical

benefit from the LP-300 triplet regimen.

● Extended

Treatment Cycles: The maximum number of LP-300 treatment cycles will be increased

from six to eight, supported by historical safety data indicating that up to eight cycles

of LP-300 at the current dose level did not alter the established safety profile of the drug.

● Study

Design Change:

The study will discontinue enrollment into the control arm while migrating into

a single arm study and only enroll additional patients with EGFR exon 21 L858R mutation.

This change reflects the evolution of the treatment landscape for TKI-refractory

NSCLC that has made continued randomization to the control arm increasingly challenging.

The

HARMONIC™ trial is ongoing at clinical sites in the United States, Japan, and Taiwan. Targeted enrollment in Japan was completed

in July 2025 across five clinical sites, including the National Cancer Center Tokyo, and the trial continues to enroll patients in the

U.S., as well as in Taiwan, where more than 50% of lung cancer cases occur in never-smokers. The trial has previously demonstrated

encouraging results in its initial safety lead-in cohort, showing an 86% clinical benefit rate and 43% objective response rate among

the first seven patients enrolled in the United States, including one patient who achieved a durable complete response in target cancer

lesions with survival continuing for nearly two years.

Lantern

is actively exploring collaboration and partnering opportunities both globally and regionally to maximize LP-300’s commercial potential

in multiple geographies. Additional clinical data updates from the HARMONIC™ trial are expected in the second half of 2026.

Never-smoker

NSCLC is increasingly recognized as a distinct disease entity with unique clinical and genomic characteristics, representing a global

market opportunity estimated at over $4 billion annually. Currently, there are no therapies specifically approved for never-smoker NSCLC

patients.

Starlight

Therapeutics: FDA IND Clearance for Pediatric CNS Cancer Trial and Expanded Adult GBM Program

early 2026, the FDA cleared the Investigational New Drug (IND) application for Starlight Therapeutics’ planned Phase 1 pediatric

CNS cancer trial of STAR-001 (LP-184) in Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers, marking a pivotal

regulatory milestone for Lantern’s wholly-owned subsidiary. STAR-001 has received both Rare Pediatric Disease Designation and Orphan

Drug Designation from the FDA for ATRT, along with additional designations for hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid

tumors.

These

designations provide potential pathways for FDA Priority Review Vouchers (PRVs) upon a potential future approval. PRVs have historically

been sold or transferred for significant value, with recent transactions in the range of $100 million to $150 million or more, representing

a potentially meaningful source of non-dilutive value for Lantern and its shareholders independent of the commercial potential of the

underlying therapy. The Rare Pediatric Disease Designations for ATRT, hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors

each independently qualifies for a potential PRV upon potential FDA approval and meeting other program conditions.

addition to the pediatric CNS program, Starlight is advancing plans for a Phase 1b trial of STAR-001 in adult patients with relapsed

glioblastoma (GBM) in combination with spironolactone. Preclinical studies have demonstrated meaningful synergy between STAR-001 and

spironolactone in GBM models, with combination treatment producing enhanced anti-tumor activity relative to either agent alone. The combination

leverages Lantern’s RADR®-driven insights into DNA damage repair vulnerabilities in GBM, and Starlight believes

the program has the potential to address a significant unmet need in a cancer indication where median overall survival following recurrence

remains under nine months despite decades of clinical research.

Glioblastoma

remains one of the most treatment-resistant cancers, with approximately 12,000 new cases diagnosed annually in the United States and

a global incidence representing a multi-billion-dollar market opportunity. Lantern and Starlight are exploring partnership and collaboration

opportunities to accelerate the development of STAR-001 across both pediatric and adult CNS indications.

withZeta.ai:

Commercial Launch & Evolution Towards An Independent Entity

April 2026, Lantern publicly launched withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex

cancer drug development. The launch was marked by a Nasdaq MarketSite debut, a live demonstration at the American Association for Cancer

Research (AACR) 2026 Annual Meeting, and a dedicated investor and analyst webinar covering five oncology use cases ranging from biomarker

discovery to clinical trial design optimization. Since its introduction, withZeta.ai has been actively used and evaluated by biotech

companies, cancer research centers, biopharma consultants, and institutional investors across the United States, Europe, and Asia.

withZeta.ai

is designed to accelerate drug development insights, therapeutic strategy generation, cancer trial development, and research workflows

across more than 438 rare cancer indications — a category of diseases that collectively represents a massive unmet medical need,

but where individual indications have historically been underserved due to small patient populations, sparse and scattered data, and

limited commercial incentives. The platform combines multiple specialized AI agents that work collaboratively to analyze genomic data,

identify potential therapeutic targets, predict drug-tumor interactions, and generate actionable development strategies, drawing on Lantern’s

unique expertise and proprietary data assets in rare and orphan cancer drug development.

Planned

Separation into an Independent Business Entity

connection with the May 2026 financing, Lantern announced a strategic plan to separate withZeta.ai and related personnel

into an independent business entity under the leadership of Panna Sharma. The separation is intended to provide withZeta.ai with dedicated

funding sources and the opportunity to realize valuation multiples distinct from Lantern’s clinical-stage drug development operations.

This

reflects Lantern’s broader strategic evolution toward operating two distinct value-creation engines: 1) a clinical-stage

drug development business aimed at advancing therapies across solid tumors, blood cancers, and CNS cancers; and 2) an AI

platform business addressing the multi-billion-dollar opportunity in AI-enabled drug discovery and cancer research. Lantern believes

that withZeta.ai is positioned at the intersection of two high-growth markets — the global rare disease therapeutics market, and

the broader AI-enabled drug discovery and pharmaceutical R&D outsourcing market. Analysts estimate that the AI-enabled outsourcing

and platform market for pharmaceutical companies will be in the range of $20 to $30 billion by 2030.

Lantern

plans to host a dedicated investor webinar during the first half of June 2026 to provide additional detail on the withZeta.ai platform’s

commercial trajectory, the contemplated independent business entity, the strategic rationale for the planned separation, and anticipated

next steps. Registration details will be communicated through the Company’s investor relations channels in advance of the webinar.

predictBBB.ai:

Evolution into a Molecular Intelligence Web Service Powered by a Large Quantitative Model

During

the first quarter of 2026, Lantern completed a major expansion of predictBBB.ai, repositioning the platform from a focused blood-brain

barrier permeability prediction tool into a first-of-its-kind molecular intelligence web service powered by a Large Quantitative Model

(LQM). The expanded platform extends beyond BBB permeability prediction to a broader set of molecular and structural analyses designed

to accelerate small molecule drug design and optimization for CNS and non-CNS indications alike.

The

underlying LQM architecture is purpose-built for the prediction of quantitative molecular properties — including permeability,

solubility, binding affinity, metabolic stability, and structural similarity — across a wide range of therapeutic chemistry contexts.

By moving from a single-property predictor to a multi-property intelligence service, predictBBB.ai is now positioned to serve a broader

user base of medicinal chemists, computational scientists, and translational researchers working across oncology, neurology, and other

therapeutic areas.

predictBBB.ai

continues to demonstrate industry-leading performance benchmarks, holding five of the top eleven positions on the Therapeutic Data Commons

Leaderboard for blood-brain barrier permeability prediction, with the lead model achieving 94.1% accuracy. The platform is accessible

through a web-based service interface designed for ease of use by both individual researchers and enterprise drug discovery teams.

The

repositioning of predictBBB.ai complements Lantern’s broader AI platform strategy alongside the RADR® platform and

withZeta.ai, reinforcing the Company’s position as a creator and innovator of differentiated, oncology- and rare-disease-focused

AI infrastructure for global biopharma drug development.

Financial

Results for the First Quarter Ended March 31, 2026

Balance

Sheet: Cash, cash equivalents, and marketable securities were approximately $6.3 million as of March 31, 2026 (consisting of approximately

$4.9 million in cash and cash equivalents and approximately $1.4 million in marketable securities), compared to approximately $10.1 million

as of December 31, 2025. The Company received gross proceeds of approximately $4.4 million in a registered direct offering that closed

on May 14, 2026. The Company believes its cash, cash equivalents, and marketable securities on hand, including the net proceeds from

the offering, will fund anticipated operating expenses and capital expenditure requirements until approximately the middle of the first

quarter of 2027.

Research

and Development Expenses: R&D expenses were approximately $1.7 million for the three months ended March 31, 2026, compared to

approximately $3.3 million for the three months ended March 31, 2025, a decrease of approximately $1.5 million or 47%. The decrease was

primarily attributable to reductions of approximately $1,322,000 in research studies and materials relating to the conduct of our clinical

trials and decreases of approximately $246,000 in salaries and benefit expenses.

General

and Administrative Expenses: G&A expenses were approximately $1.7 million for the three months ended March 31, 2026, compared

to approximately $1.5 million for the three months ended March 31, 2025, an increase of approximately $170,000 or 11%. The increase was

primarily attributable to increases in patent costs of approximately $99,000, salaries and benefit expense increases of approximately

$71,000, and business development and investor relations expenditure increases of approximately $36,000.

Net

Loss: Net loss was approximately $3.3 million (or $0.30 per share) for the three months ended March 31, 2026, compared to a net loss

of approximately $4.5 million (or $0.42 per share) for the three months ended March 31, 2025, representing a year-over-year reduction

of approximately $1.2 million or 27%.

Capitalization:

As of May 12, 2026, the Company had 11,304,697 shares of common stock outstanding. On May 14, 2026, the Company closed a registered

direct offering and concurrent private placement comprising 1,454,175 shares of common stock, pre-funded warrants to purchase up to 681,748

shares of common stock, and unregistered warrants to purchase up to 2,135,923 additional shares of common stock at an exercise price

of $2.27 per share. The warrants are exercisable beginning six months after issuance and expire five years from the initial exercise

date.

2026

Corporate Objectives and Catalysts

● Second

Half 2026: Additional clinical data readouts from the Phase 2 HARMONIC™ trial following

implementation of the protocol amendments focusing enrollment on EGFR exon 21 L858R never-smoker

NSCLC patients.

● First

Half of June 2026: Dedicated investor webinar on withZeta.ai commercial trajectory, the

contemplated independent business entity, and the strategic rationale for the anticipated

benefits of the planned separation.

● 2026:

Investigator-led clinical study initiation in Denmark for LP-184 in PTGR1-overexpressing

bladder cancers with DNA damage repair mutations.

● 2026:

Execution of the strategic plan to create an independent business entity composed of

withZeta.ai assets and related technologies, including announcement of additional structural

and listing details.

● 2026:

Planned initiation of additional clinical trials for LP-184 and STAR-001.

● 2026:

Continued commercialization of the withZeta.ai multi-agentic co-scientist platform, including

conversion of demo and evaluation engagements to commercial subscription contracts and expansion

across the rare cancer research community.

● 2026:

Continued scale-up of the AI Center of Excellence in India to industrialize the RADR®

platform and withZeta.ai system and accelerate global biopharma development opportunities.

● 2026:

Pursuit of additional funding, including potential grant revenue, partnership transactions,

and additional capital raises, to support planned operations and clinical advancement.

About

Lantern Pharma

Lantern

Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. Our

proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and

a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development and generate

oncology medicines at dramatically reduced costs and accelerated timelines. By harnessing the power of AI and with input from world-class

scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple

cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly

developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately

$1.0–2.5 million per program.

Our

lead development programs include a Phase 2 clinical program in never-smoker and non-smoker NSCLC, planned Phase 1b/2 trials in biomarker-defined

solid tumors, and an ongoing Phase 1 program in hematologic malignancies and adult soft tissue sarcomas. We have also established a wholly-owned

subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers.

In April 2026, Lantern publicly launched withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex

cancer drug development. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential

of over $15 billion USD.

Website:

www.lanternpharma.com

Harmonic

Trial: www.harmonictrial.com

LinkedIn:

https://www.linkedin.com/company/lanternpharma/

@lanternpharma

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating

to: future events or our future financial performance; the potential advantages of our RADR® platform and withZeta.ai

platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription

models; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program;

the planned commercialization of our AI platforms including withZeta.ai and the expected market opportunity for AI co-scientist platforms;

the planned separation of withZeta.ai into an independent business entity and the anticipated benefits of such separation; the planned

investor webinar regarding withZeta.ai; estimates regarding the development timing for our drug candidates, AI platforms, and

ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; the use of proceeds from

the May 2026 registered direct offering and the expected time that our cash, cash equivalents and marketable securities will allow

us to fund our operations; the potential exercise of warrants issued in the May 2026 concurrent private placement; our research

and development efforts of our internal drug discovery programs and the utilization of our AI platforms to streamline the drug

development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform

the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a

drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates

and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves

or in collaboration with others.

Any

statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”

“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”

“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”

“target,” “model,” “objective,” “aim,” “upcoming,” “should,”

“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking

statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by

the forward-looking statements, such as (i) the existence of substantial doubt about our ability to continue as a going concern in the

absence of obtaining substantial additional funding, (ii) the risk that we may not be able to secure sufficient future funding when needed

and as required to advance and support our existing and planned clinical trials and operations, (iii) the risk that observations in preclinical

studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will

be consistent or successful, (iv) the risk that our research and the research of our collaborators may not be successful, (v) the risk

that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (vi) the

risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct,

or conclude clinical testing for or obtain marketing approval for our product candidates, (vii) the risk that no drug product based on

our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into a commercial product, (viii)

the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the

expected market adoption, (ix) the risk that the planned separation of withZeta.ai may not be completed on the contemplated terms or

timeline or at all, and (x) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year

ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026 and in the Quarterly Report on Form

10-Q for the quarter ended March 31, 2026.

You

may access our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter

ended March 31, 2026 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov.

Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that

any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors

not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the

date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform

the statement to actual results or changes in our expectations.

Lantern

Pharma Disclosure Channels to Disseminate Information

Lantern

Pharma’s investors and others should note that we announce material information to the public about our company through a variety

of means, including our website, press releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary

distribution of information to the public. We encourage our investors and others to review the information we make public in the locations

above as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Investor

Contact

Investor

Relations

ir@lanternpharma.com

+1-972-277-1136

Source:

Lantern Pharma Inc.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 15, 2026

Entity File Number

001-39318

Entity Registrant Name

Lantern

Pharma Inc.

Entity Central Index Key

0001763950

Entity Tax Identification Number

46-3973463

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1920

McKinney Avenue

Entity Address, Address Line Two

7th Floor

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

(972)

Local Phone Number

277-1136

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

LTRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration